Neuberger Berman Group
RNTX

Neuberger Berman Group’s Rein Therapeutics RNTX Stock Holding History

Neuberger Berman Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,250
Closed -$279K – 1653
2017
Q2 		$279K Buy
+1,250
New +$274K ﹤0.01% 1430

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Neuberger Berman Group's RNTX Position: Q3 2017 in Review

Neuberger Berman Group sold out of Rein Therapeutics (RNTX) in Q3 2017, closing a stake of 1,250 shares — an estimated $279K sold.

Neuberger Berman Group first reported a position in RNTX in Q2 2017 and held it in 1 quarter. The position peaked at $279K in Q2 2017. 31 funds tracked by Wall St. Rank hold RNTX as of Q3 2017.

  • Neuberger Berman Group reported no remaining Rein Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 1,250 Rein Therapeutics shares in Q3 2017, an estimated $279K.
  • Neuberger Berman Group first reported a position in Rein Therapeutics in Q2 2017 and held it in 1 quarter.
  • Neuberger Berman Group's Rein Therapeutics position peaked at $279K in Q2 2017.
  • 31 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2017.

Based on Neuberger Berman Group's 13F filing for Q3 2017, filed 15 Nov 2017.